Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced a collaboration agreement with CtM Biotech (Shanghai) Co., Ltd (hereafter referred to as “CtM Bio”) to jointly develop innovative antibody drugs against intracellular tumor-associated antigens. Under this agreement, Biocytogen will be responsible for screening fully human antibodies against specific targets by leveraging the company’s proprietary TCR-mimic antibody development platform. CtM Bio will use their proprietary T cell engager platform to co-develop T cell engagers targeting intracellular tumor-associated antigens.
Biocytogen’s TCR-mimic antibody development platform, which utilizes a strain of fully human RenMabTM mice expressing a human leukocyte antigen (HLA) gene, is designed to facilitate the discovery of antibodies against intracellular tumor-associated antigens. CtM Bio has extensive experience in the discovery of innovative drug candidates for the treatment of life-threatening diseases. The company has developed a proprietary T cell engager platform with differentiated properties which is expected to turn “cold tumors” into “hot tumors”, possibly overcoming the current limitation of immunotherapy.
Under this collaboration, Biocytogen and CtM Bio will jointly promote the development of novel antibody drugs that could significantly expand the potential of immunotherapy, ultimately helping to improve the lives of patients suffering from cancer and other debilitating diseases.